JP2010507593A5 - - Google Patents

Download PDF

Info

Publication number
JP2010507593A5
JP2010507593A5 JP2009533595A JP2009533595A JP2010507593A5 JP 2010507593 A5 JP2010507593 A5 JP 2010507593A5 JP 2009533595 A JP2009533595 A JP 2009533595A JP 2009533595 A JP2009533595 A JP 2009533595A JP 2010507593 A5 JP2010507593 A5 JP 2010507593A5
Authority
JP
Japan
Prior art keywords
composition
compound according
pharmaceutical composition
compound
erectile dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009533595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507593A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/082157 external-priority patent/WO2008070313A2/en
Publication of JP2010507593A publication Critical patent/JP2010507593A/ja
Publication of JP2010507593A5 publication Critical patent/JP2010507593A5/ja
Pending legal-status Critical Current

Links

JP2009533595A 2006-10-20 2007-10-22 3−(ジヒドロ−1H−ピラゾロ[4,3−d]ピリミジン−5−イル)−4−プロポキシベンゼンスルホンアミド誘導体および使用方法 Pending JP2010507593A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85323406P 2006-10-20 2006-10-20
PCT/US2007/082157 WO2008070313A2 (en) 2006-10-20 2007-10-22 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use

Publications (2)

Publication Number Publication Date
JP2010507593A JP2010507593A (ja) 2010-03-11
JP2010507593A5 true JP2010507593A5 (enExample) 2010-12-16

Family

ID=39492926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533595A Pending JP2010507593A (ja) 2006-10-20 2007-10-22 3−(ジヒドロ−1H−ピラゾロ[4,3−d]ピリミジン−5−イル)−4−プロポキシベンゼンスルホンアミド誘導体および使用方法

Country Status (9)

Country Link
US (1) US8552008B2 (enExample)
EP (1) EP2089392A4 (enExample)
JP (1) JP2010507593A (enExample)
KR (1) KR20090091138A (enExample)
CN (1) CN101528747A (enExample)
AU (1) AU2007329728A1 (enExample)
CA (1) CA2664940A1 (enExample)
MX (1) MX2009003941A (enExample)
WO (1) WO2008070313A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090270425A1 (en) * 2006-10-20 2009-10-29 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20090197899A1 (en) * 2006-10-20 2009-08-06 Concert Pharmaceuticals Inc. 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
KR101071877B1 (ko) * 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
JP7526673B2 (ja) 2018-02-20 2024-08-01 インサイト・コーポレイション がんを治療するためのhpk1阻害剤としてのn-(フェニル)-2-(フェニル)ピリミジン-4-カルボキサミド誘導体及び関連化合物
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP2009502961A (ja) 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20090270425A1 (en) * 2006-10-20 2009-10-29 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20080280927A1 (en) 2006-10-20 2008-11-13 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20090197899A1 (en) * 2006-10-20 2009-08-06 Concert Pharmaceuticals Inc. 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use

Similar Documents

Publication Publication Date Title
EP2397476A3 (en) Indole derivative having PGD2 receptor antagonist activity
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
JP2010504343A5 (enExample)
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
EP2269610A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP2006523216A5 (enExample)
ES2877642T3 (es) Formulaciones de 2-(terc-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
JP2009502961A5 (enExample)
JP2006526590A5 (enExample)
JP2007145875A5 (enExample)
JP2010077141A5 (enExample)
EP2266569A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP2007516180A5 (enExample)
JP2008510691A5 (enExample)
AR057873A2 (es) Compuestos derivados de piperizina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos
JP2019515908A5 (enExample)
JP2017527532A5 (enExample)
JP2010501478A5 (enExample)
WO2005077950A3 (en) Medicaments with hm74a receptor activity
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
JP2003306481A5 (enExample)
JP2008513510A5 (enExample)
MX2007004740A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica.
HUE026645T2 (en) Estrra-1,3,5 (10), 16-tetraene-3-carboxamide derivatives, a process for their preparation, pharmaceutical compositions containing them, and their use in the manufacture of a medicament.
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them